"No Going Back?" The final report of the Effective Records Management Project

The overall objective of the Effective Records Management project was the provision of ‘protocols and tools for the effective management of information in the digital order, with particular attention to information held in a document-based form’ . The project developed a demonstrator system which addressed the full range of issues involved in the management of a ‘testbed’ of digital records in the form of documents, from their creation through distribution and use to their final disposal or permanent retention. The testbed selected was the records of a subset of the university’s committees and was used to develop ideas and to assess how well they worked in practice. This project report indicates that the ERM project provides an investment in the future, opportunities for better information use or re-use, identification of legal risks and identification of good practice whether you be an administrator, a computing scientist, an archivist, a librarian or an information services manager

"No Going Back?" The final report of the Effective Records Management Project

The overall objective of the Effective Records Management project was the provision of ‘protocols and tools for the effective management of information in the digital order, with particular attention to information held in a document-based form’ . The project developed a demonstrator system which addressed the full range of issues involved in the management of a ‘testbed’ of digital records in the form of documents, from their creation through distribution and use to their final disposal or permanent retention. The testbed selected was the records of a subset of the university’s committees and was used to develop ideas and to assess how well they worked in practice. This project report indicates that the ERM project provides an investment in the future, opportunities for better information use or re-use, identification of legal risks and identification of good practice whether you be an administrator, a computing scientist, an archivist, a librarian or an information services manager

Risk of COVID-19 after natural infection or vaccinationResearch in context

Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health